US Stock Market Move | Diabetes treatment technology achieves major breakthroughs. Sana Biotechnology (SANA.US) surged more than 232%.

On Wednesday, Sana Biotechnology (SANA.US) surged over 232%, reaching $5.52. In terms of news, Sana Biotechnology released positive data on its investigational treatment for Type 1 diabetes. The company stated that it transplanted its therapy, UP421, which utilizes a low-immunogenicity biological material core therapy, to a Type 1 diabetes patient who was not using any immunosuppressive drugs. The study did not find any safety issues, and the low-immunogenicity modified core therapy evaded immune reactions.